Norway lifts ban on mail-order drugs

19 January 2009

After finally deciding that increased competition in the drug retail sector is worth reducing government control over distribution channels,  the mail-order trade in pharmaceuticals in Norway looks set to be  legalized in 2009. Although the use of the Internet has previously been  permitted for placing orders for medicines, the authorities refused to  allow the use of the postal service for the delivery of products,  forcing on-line retailers to use more expensive courier services.

Initially, the plan is to allow over-the-counter agents to be  distributed through the mail, and the necessary regulatory changes will  likely take effect in the summer of this year, a spokesman for the  Norwegian Medicines Agency (NoMA) said. If this is successful, the NoMA  anticipates extending deregulation to prescription drugs.

A spokesman for the Norwegian Association of Pharmaceutical  Manufacturers (LMI) told the Marketletter that it is monitoring changes  to the retail distribution sector very closely. The lifting of  restrictions to allow properly-licensed pharmacies to operate more  efficiently, is a development that is welcomed by drugmakers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight